GRDN vs MDLN vs AMRX Stock Comparison

Guardian Pharmacy Services, Medline and Amneal Pharmaceuticals Prices as of Nov 13, 2026 Peers: Industry group
MDLN Medline Inc.
$39.47 +9.9% 1M
Market cap
$34.37B
P/E
40.9x
Revenue (TTM)
$30.68B
Div. yield
–
Medical Supplies Healthcare
3 wins

Head to Head

10 decided of 12

Amneal Pharmaceuticals leads on 5 of the 12 questions below (Amneal Pharmaceuticals 5, Medline 3, Guardian Pharmacy Services 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionGRDNMDLNAMRXLeader
Larger companyMarket capitalisation $3.12B $34.37B $7.10B MDLN
Cheaper on earningsLower P/E, profitable companies only 41.7x 40.9x 53.2x MDLN
Cheaper on forward earningsLower price / next fiscal year consensus EPS 37.5x 26.5x 21.4x AMRX
Faster revenue growthRevenue growth, trailing twelve months +4.9% — +8.9% AMRX
More profitableNet margin, trailing twelve months 5.1% 2.7% 4.2% GRDN
Better return on capitalReturn on invested capital — 4.3% 14.3% AMRX
Less leveragedLower net debt / EBITDA — 3.2x 4.3x MDLN
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +62.6% — +85.6% AMRX
Better 5-year returnAnnualised price return, 5 years — — +32.7%/yr –
Less volatileAnnualised volatility, 1 year 42.4% 47.8% 34.3% AMRX
Higher overall scoreMean of the five percentile scores vs peers 71/100 53/100 69/100 GRDN

Percentile Scorecard

GRDNMDLNAMRX

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisGRDNMDLNAMRX
Valuation 23 #21 of 27 78 #54 of 243 90 #69 of 660
Growth 76 #7 of 26 – 70 #189 of 619
Profitability 96 #2 of 26 73 #60 of 222 87 #80 of 595
Financial Health 88 #4 of 26 43 #143 of 248 11 #606 of 683
Shareholder Returns – 17 #132 of 158 89 #53 of 459
Overall 71 53 69
  • GRDN ranked among 27 companies in Healthcare Payers and Distributors
  • MDLN ranked among 252 companies in Medical Devices and Diagnostics
  • AMRX ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodGRDNMDLNAMRXSPY
1 month +21.9%+9.9%+13.1% -2.0%
3 months +28.7%+10.4%+17.8% -2.8%
6 months +35.1%+9.1%+79.2% +2.0%
Year to date +64.4%-6.0%+69.7% +10.6%
1 year +62.6%—+85.6% +12.2%
3 years ——+367.8% +68.1%
3 years, per year ——+67.3% +18.9%
5 years ——+310.4% +61.4%
5 years, per year ——+32.7% +10.1%

Risk

MeasureGRDNMDLNAMRXSPY
Volatility, 1Y 42.4%47.8%34.3% 13.6%
Downside volatility, 1Y 39.1%48.2%30.7% 13.9%
Beta vs S&P 500, 1Y 0.710.740.67 1.00
Return / volatility, 1Y 1.48—2.49 0.90
Max drawdown, 5Y -27.2%-36.7%-75.4% -25.4%
From 52-week high -1.1%-21.0%-1.5% -3.2%
52-week high $50.01$49.99$21.71 $779.14
52-week low $27.03$31.64$11.52 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleGRDNMDLNAMRX
P/E now vs peer median 41.9xmedian 25.2x 41.1xmedian 26.5x 53.8xmedian 17.0x
P/S now vs peer median 2.2xmedian 0.4x 1.7xmedian 2.7x 2.3xmedian 8.4x
EV/EBITDA now vs peer median 25.6xmedian 14.5x 21.6xmedian 18.4x 15.1xmedian 14.6x
P/FCF now vs peer median 40.0xmedian 16.5x 27.4xmedian 25.4x 193.9xmedian 19.0x
P/B now vs peer median 11.2xmedian 2.7x 2.7xmedian 2.5x 14.0xmedian 2.0x
PEG now vs peer median —median 1.72 —median 0.98 0.65median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsGRDNMDLNAMRX
Revenue $1.46B $30.68B $3.20B
Gross profit $327.08M $7.90B $1.29B
Operating income $94.14M $1.74B $478.99M
Net income $74.77M $889.00M $175.49M
Free cash flow $78.35M $1.90B $38.42M
R&D – – $180.59M
EPS (diluted) $1.17 $0.64 $0.40
Cash & equivalents $119.66M $2.32B $157.40M
Total debt – $12.58B $3.12B
Shares (diluted) 63.92M 1.32B 335.73M
Enterprise value $2.78B $23.91B $6.33B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricGRDNMDLNAMRX
P/E 41.9x 41.1x 53.8x
P/FCF 40.0x 27.4x 193.9x
P/Operating cash flow 27.5x 21.8x 41.2x
P/S 2.2x 1.7x 2.3x
P/B 11.2x 2.7x 14.0x
P/Tangible book 12.1x 8.6x -7.3x
EV/EBITDA 25.6x 21.6x 15.1x
EV/EBIT 32.0x 35.0x 21.7x
EV/Revenue 2.1x 2.0x 3.3x
EV/FCF 38.5x 32.1x 271.0x
EV/Operating cash flow 26.4x 25.6x 57.6x
PEG (3Y EPS CAGR) – – 0.65

Growth

14 metrics
MetricGRDNMDLNAMRX
Revenue growth (1Y) 4.9% – 8.9%
Revenue CAGR (3Y) – – 10.2%
Gross profit growth (1Y) 19.2% – 19.2%
Gross profit CAGR (3Y) – – 15.0%
Operating income growth (1Y) 60.4% – 33.8%
Operating income CAGR (3Y) – – 28.4%
Net income growth (1Y) 85.8% – 271.2%
Net income CAGR (3Y) – – 53.6%
EPS growth (1Y) 84.4% – 2,085%
EPS CAGR (3Y) – – 83.1%
Operating cash flow growth (1Y) 29.6% – -44.9%
Operating cash flow CAGR (3Y) – – -1.1%
Free cash flow growth (1Y) 18.9% – -84.6%
Free cash flow CAGR (3Y) – – -35.0%

Profitability

14 metrics
MetricGRDNMDLNAMRX
Gross margin 22.4% 25.7% 40.2%
EBITDA margin 8.1% 9.2% 21.5%
Operating margin 6.5% 5.7% 15.0%
Pretax margin 7.2% 3.6% 6.9%
Net margin 5.1% 2.7% 4.2%
FCF margin 5.4% 6.2% 1.2%
Operating cash flow margin 7.8% 7.8% 5.7%
Return on equity 28.3% 4.6% 74.3%
Return on assets 16.3% 2.2% 4.6%
Return on invested capital – 4.3% 14.3%
Return on capital employed 32.6% 4.8% 14.1%
Asset turnover 3.1x 0.8x 0.7x
Cash conversion (OCF / net income) 1.5x 2.7x 1.0x
Stock comp / revenue 0.6% 0.4% 1.2%

Financial Health

11 metrics
MetricGRDNMDLNAMRX
Debt / assets – 31.3% 59.2%
Debt / equity – 0.6x 5.9x
Net debt / EBITDA – 3.2x 4.3x
Debt / FCF – 6.6x 81.2x
Liabilities / assets 43.1% 51.7% 89.9%
Equity / assets 56.9% 48.3% 10.1%
Interest coverage 145.3x – –
Current ratio 1.6x 4.0x 1.9x
Quick ratio 1.3x 2.4x 1.1x
Cash ratio 0.7x 1.2x 0.1x
Altman Z-score 13.09 2.70 1.96

Shareholder Returns

7 metrics
MetricGRDNMDLNAMRX
Dividend yield – – –
Net buyback yield – -13.6% 0.0%
Shareholder yield – -13.6% 0.0%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusGRDNMDLNAMRX
Forward P/E 37.5xFY2026 26.5xFY2026 21.4xFY2026
EPS, next fiscal year $1.32FY2026 $1.49FY2026 $1.00FY2026
EPS growth, next FY +23.4%FY2026 +4.2%FY2026 +20.5%FY2026
EPS growth, the year after +18.9% +9.4% +26.0%
Revenue, next fiscal year $1.42BFY2026 $32.69BFY2026 $3.30BFY2026
Revenue growth, next FY -2.2%FY2026 +15.0%FY2026 +9.1%FY2026
Revenue growth, the year after +2.7% +8.2% +12.6%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersGRDNMDLNAMRX
Held by institutions 58.6% 57.1% 51.0%
Institutions holding 189 409 310
Change in shares held, QoQ +3.8% +17.9% +1.3%
Institutions buying 109 322 182
Institutions selling 54 69 86
Buyers to sellers 2.02 4.67 2.12

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

GRDNMDLNAMRX
GRDN 1.00 0.12 0.17
MDLN 0.12 1.00 0.19
AMRX 0.17 0.19 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, GRDN, MDLN and AMRX?

Medline (MDLN) is the largest by market capitalisation: Guardian Pharmacy Services (GRDN) $3.12B, Medline (MDLN) $34.37B, Amneal Pharmaceuticals (AMRX) $7.10B.

Which stock is cheaper, GRDN, MDLN and AMRX?

Medline (MDLN) trades on the lowest price-to-earnings ratio (Guardian Pharmacy Services (GRDN) 41.7x, Medline (MDLN) 40.9x, Amneal Pharmaceuticals (AMRX) 53.2x). On next year's consensus earnings, Amneal Pharmaceuticals (AMRX) is cheapest (Guardian Pharmacy Services (GRDN) 37.5x, Medline (MDLN) 26.5x, Amneal Pharmaceuticals (AMRX) 21.4x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Amneal Pharmaceuticals (AMRX) grew revenue fastest over the trailing twelve months: Guardian Pharmacy Services (GRDN) +4.9%, Amneal Pharmaceuticals (AMRX) +8.9%.

Which company is more profitable?

Guardian Pharmacy Services (GRDN) has the highest net margin (Guardian Pharmacy Services (GRDN) 5.1%, Medline (MDLN) 2.7%, Amneal Pharmaceuticals (AMRX) 4.2%). On return on invested capital, Amneal Pharmaceuticals (AMRX) leads (Medline (MDLN) 4.3%, Amneal Pharmaceuticals (AMRX) 14.3%).

Which stock has performed better?

Over the past year Amneal Pharmaceuticals (AMRX) returned the most: Guardian Pharmacy Services (GRDN) +62.6%, Amneal Pharmaceuticals (AMRX) +85.6%. Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Amneal Pharmaceuticals (AMRX) has been the steadiest (Guardian Pharmacy Services (GRDN) 42.4%, Medline (MDLN) 47.8%, Amneal Pharmaceuticals (AMRX) 34.3%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, GRDN, MDLN and AMRX?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Amneal Pharmaceuticals (AMRX) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.